Despite the substantial incidence of stroke-related death and disability56, treatment options are limited to mechanical stenting or pharmacologic therapy with tissue plasminogen activator (tPA), albeit with limited temporal windows and hemorrhage risk57–59. The gene discussed is PLAT; the disease is stroke disorder.